<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article">
 <front>
  <journal-meta>
   <journal-id journal-id-type="publisher-id">
    ojneph
   </journal-id>
   <journal-title-group>
    <journal-title>
     Open Journal of Nephrology
    </journal-title>
   </journal-title-group>
   <issn pub-type="epub">
    2164-2842
   </issn>
   <issn publication-format="print">
    2164-2869
   </issn>
   <publisher>
    <publisher-name>
     Scientific Research Publishing
    </publisher-name>
   </publisher>
  </journal-meta>
  <article-meta>
   <article-id pub-id-type="doi">
    10.4236/ojneph.2024.143037
   </article-id>
   <article-id pub-id-type="publisher-id">
    ojneph-136449
   </article-id>
   <article-categories>
    <subj-group subj-group-type="heading">
     <subject>
      Articles
     </subject>
    </subj-group>
    <subj-group subj-group-type="Discipline-v2">
     <subject>
      Medicine 
     </subject>
     <subject>
       Healthcare
     </subject>
    </subj-group>
   </article-categories>
   <title-group>
    Correlation between Wnt Signalling Inhibitors (Dickkopf-1&amp;Sclerostin) and the Intimal Medial Thickness in Children on Maintenance Hemodialysis
   </title-group>
   <contrib-group>
    <contrib contrib-type="author" xlink:type="simple">
     <name name-style="western">
      <surname>
       Manal Abd
      </surname>
      <given-names>
       El-Salam
      </given-names>
     </name> 
     <xref ref-type="aff" rid="aff1"> 
      <sup>1</sup>
     </xref>
    </contrib>
    <contrib contrib-type="author" xlink:type="simple">
     <name name-style="western">
      <surname>
       Mohamed Hamdi
      </surname>
      <given-names>
       Ali
      </given-names>
     </name> 
     <xref ref-type="aff" rid="aff2"> 
      <sup>2</sup>
     </xref>
    </contrib>
    <contrib contrib-type="author" xlink:type="simple">
     <name name-style="western">
      <surname>
       Nadia Youssef
      </surname>
      <given-names>
       Riad
      </given-names>
     </name> 
     <xref ref-type="aff" rid="aff3"> 
      <sup>3</sup>
     </xref>
    </contrib>
    <contrib contrib-type="author" xlink:type="simple">
     <name name-style="western">
      <surname>
       Rasha Abd El Samad
      </surname>
      <given-names>
       Fawaz
      </given-names>
     </name> 
     <xref ref-type="aff" rid="aff1"> 
      <sup>1</sup>
     </xref>
    </contrib>
    <contrib contrib-type="author" xlink:type="simple">
     <name name-style="western">
      <surname>
       Shima
      </surname>
      <given-names>
       Mohamed
      </given-names>
     </name> 
     <xref ref-type="aff" rid="aff4"> 
      <sup>4</sup>
     </xref>
    </contrib>
   </contrib-group> 
   <aff id="aff1">
    <addr-line>
     aDepartment of Pediatrics, Faculty of Medicine (for Girls), Al-Azhar University, Cairo, Egypt
    </addr-line> 
   </aff> 
   <aff id="aff2">
    <addr-line>
     aTbilisi State Medical University, Tbilisi, Georgia
    </addr-line> 
   </aff> 
   <aff id="aff3">
    <addr-line>
     aDepartment of Clinical Pathology, National Heart Institute, Cairo, Egypt
    </addr-line> 
   </aff> 
   <aff id="aff4">
    <addr-line>
     aDepartment of Radiology, Faculty of Medicine (for Girls), Al-Azhar University, Cairo, Egypt
    </addr-line> 
   </aff> 
   <pub-date pub-type="epub">
    <day>
     30
    </day> 
    <month>
     07
    </month>
    <year>
     2024
    </year>
   </pub-date> 
   <volume>
    14
   </volume> 
   <issue>
    03
   </issue>
   <fpage>
    397
   </fpage>
   <lpage>
    412
   </lpage>
   <history>
    <date date-type="received">
     <day>
      26,
     </day>
     <month>
      August
     </month>
     <year>
      2024
     </year>
    </date>
    <date date-type="published">
     <day>
      27,
     </day>
     <month>
      August
     </month>
     <year>
      2024
     </year> 
    </date> 
    <date date-type="accepted">
     <day>
      27,
     </day>
     <month>
      September
     </month>
     <year>
      2024
     </year> 
    </date>
   </history>
   <permissions>
    <copyright-statement>
     © Copyright 2014 by authors and Scientific Research Publishing Inc. 
    </copyright-statement>
    <copyright-year>
     2014
    </copyright-year>
    <license>
     <license-p>
      This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/
     </license-p>
    </license>
   </permissions>
   <abstract>
    <b>Background:</b> Wnt signalling inhibitors (Dickkopf-1 and Sclerostin) signalling play a role in vascular development and may contribute to calcification. 
    <b>Aim:</b> To investigate the association between Dickkopf-1 and sclerostin serum concentrations in children undergoing maintenance hemodialysis with intimal medial thickness and peak systolic velocity of the main arteries. 
    <b>Patients and Methods:</b> A study was conducted on 40 children undergoing maintenance hemodialysis and controls of the same age and sex. The study measured the initial medial thickness (IMT) and peak systolic velocity (PSV) of the main vessels (carotid, ulnar, and femoral). Dickkopf-1 and sclerostin serum levels in both groups were assessed, and a routine investigation was performed. 
    <b>Results:</b> The findings indicate that the levels of serum Dickkopf-1 and Sclerostin were significantly higher in the hemodialysis group 2540.65 (2215.4 - 2909.2 pg/ml) and 1.17 (0.85 - 2.03 ng/ml)respectively (P = 0.001), compared to their control group it was 1110.45 (885.45 - 1527.65 pg/ml) and 0.28 (0.25 - 0.32 ng/ml)) respectively P = 0.001. Additionally, there was a significant increase in intima-media thickness (IMT) with a decrease in peak systolic velocity (PSV) in the main blood vessels, including the carotid, ulnar, and femoral arteries. A significant correlation was also observed between Dickkopf-1 and sclerostin levels and IMT of the carotid, ulnar, and femoral arteries. 
    <b>Conclusion:</b> Wnt signalling inhibitors (Dickkopf-1 and Sclerostin) exert effects beyond the bone and significantly contribute to early vascular calcification in pediatric patients undergoing maintenance hemodialysis.
   </abstract>
   <kwd-group> 
    <kwd>
     Wnt Signalling
    </kwd> 
    <kwd>
      Vascular Calcification
    </kwd> 
    <kwd>
      Hemodialysis
    </kwd> 
    <kwd>
      Children
    </kwd>
   </kwd-group>
  </article-meta>
 </front>
 <body>
  <sec id="s1">
   <title>1. Background</title>
   <p>
    <xref ref-type="bibr" rid="scirp.136449-"></xref>Patients with chronic kidney disease (CKD) have a higher likelihood of experiencing cardiovascular events. This increased risk cannot be solely attributed to traditional risk factors like age, hypertension, and diabetes. Other factors related to CKD and the chronic inflammatory state of ‘uremia’ may also contribute to this heightened risk <xref ref-type="bibr" rid="scirp.136449-1">
     [1]
    </xref> <xref ref-type="bibr" rid="scirp.136449-2">
     [2]
    </xref>.</p>
   <p>Premature arterial stiffening is primarily caused by disrupted calcium phosphate balance, which is critical in mediating these associations <xref ref-type="bibr" rid="scirp.136449-3">
     [3]
    </xref>.</p>
   <p>In chronic kidney disease (CKD), there is a risk of early-stage damage and calcification of blood vessels, which can quickly progress once dialysis is initiated <xref ref-type="bibr" rid="scirp.136449-4">
     [4]
    </xref> <xref ref-type="bibr" rid="scirp.136449-5">
     [5]
    </xref>.</p>
   <p>It’s essential to boost our knowledge of the mechanisms involved, create reliable diagnostic methods, and establish effective prevention and treatment strategies. Recognising and addressing these risk factors is vital for reducing the risk of cardiovascular disease in patients <xref ref-type="bibr" rid="scirp.136449-6">
     [6]
    </xref> <xref ref-type="bibr" rid="scirp.136449-7">
     [7]
    </xref>.</p>
   <p>The Wnt signalling pathway plays a role in bone turnover. Calcifying smooth muscle cells is similar to osteoblasts, and increasing evidence suggests Wnt’s involvement in vascular calcification. Different studies have identified various inducers, inhibitors, and regulatory proteins related to Wnt and other signalling pathways <xref ref-type="bibr" rid="scirp.136449-8">
     [8]
    </xref>.</p>
   <p>“Dickkopf-1 and sclerostin are essential glycoproteins that play a pivotal role in regulating bone formation by counteracting Wnt/β-catenin signalling in osteoblasts and osteoclasts <xref ref-type="bibr" rid="scirp.136449-9">
     [9]
    </xref>.”</p>
   <p>
    <xref ref-type="bibr" rid="scirp.136449-"></xref>Dickkopf-1, a secretory glycoprotein, can block the Wnt pathway by competitively binding to receptors (e.g., LRP5/6, Kremen) on the cell membrane <xref ref-type="bibr" rid="scirp.136449-10">
     [10]
    </xref>.</p>
   <p>Dickkopf-1 promotes inflammation in atherosclerotic plaques and is an atherogenic factor <xref ref-type="bibr" rid="scirp.136449-11">
     [11]
    </xref>. In a previous clinical study of patients with ACS, we found that DKK1 plasma levels were not only correlated with disease severity but also served as a prognostic predictor. Thus, DKK1 concentration may reflect the severity and stability of coronary atherosclerosis <xref ref-type="bibr" rid="scirp.136449-12">
     [12]
    </xref>.</p>
   <p>Sclerostin, a glycoprotein secreted by osteocytes, robustly binds to the transmembrane receptors of osteoblasts, LRP5/6, and effectively suppresses osteoblast proliferation, maturation, and differentiation. This inhibition results in the blockade of bone formation by interrupting the Wnt/β-catenin signalling pathway <xref ref-type="bibr" rid="scirp.136449-13">
     [13]
    </xref>.</p>
   <p>Vascular smooth muscle cells (VSMCs) line the walls of arteries and regulate blood pressure. During calcification, these cells can undergo a transformation similar to that of bone-forming cells, much like mesenchymal stem cells transform into osteoblast cells during bone formation.</p>
   <p>In atherosclerosis, the transformation of VSMCs into osteoblast-like cells leads to the expression of sclerostin, which inhibits the Wnt pathway <xref ref-type="bibr" rid="scirp.136449-14">
     [14]
    </xref> <xref ref-type="bibr" rid="scirp.136449-15">
     [15]
    </xref>.</p>
   <p>The published data highlight that the upregulation of Wnt components facilitates the initiation and progression of atherosclerosis, arterial remodelling, VSMC proliferation and phenotypic transition to the osteoblastic lineage in the arterial wall <xref ref-type="bibr" rid="scirp.136449-16">
     [16]
    </xref>.</p>
   <p>In most, but not all, cross-sectional observational studies, circulating sclerostin levels are positively associated with cardiovascular calcification <xref ref-type="bibr" rid="scirp.136449-17">
     [17]
    </xref> <xref ref-type="bibr" rid="scirp.136449-18">
     [18]
    </xref>. This may be due to variations in the study design, the unique populations and models studied, and the heterogeneous methods used.</p>
   <p>We hypothesised that sclerostin and Dickkopf-1, which are Wnt antagonists in circulation, may contribute to vascular calcification in children undergoing maintenance hemodialysis.</p>
  </sec><sec id="s2">
   <title>2. Methods</title>
   <p>This case-control study included 80 children. Of these, 40 were children with end-stage renal disease and were undergoing maintenance hemodialysis. The controls were of the same age and sex and were clinically healthy. These children were selected from the Pediatric Hemodialysis Unit and outpatient general clinic of AL-Zahraa Hospital, Al-Azhar University Cairo, Egypt. The age range of the patients was 4-16 years; 13 (32.5%) were female, and 27 (67.5%) were male, and they received dialysis three times a week for four hours per session at least three months at the time of the study <xref ref-type="bibr" rid="scirp.136449-19">
     [19]
    </xref>. A low-flux polysulfone dialyzer on the Fresenius 4008S was used for some patients, while a high-flux dialyzer was used on the Fresenius 5008 machine. The most common cause of end-stage renal disease was acquired in 15 patients (37.5%), followed by focal segmental glomerulosclerosis in 10 patients (25%), interstitial nephritis in 3 patients (7.5%), mesangial proliferative glomerulonephritis in 2 patients (5%), and congenital causes in 12 patients (30%), including vesicoureteral reflux in 5 patients (12.5%), multicystic dysplastic kidney in 5 patients (12.5%), and posterior urethral valve in 2 patients (5%). The cause was unknown in 11 cases (27.5%), whereas Joubert syndrome was responsible for 2 cases (5%). This study was conducted with the participation of the pediatric (nephrology and hemodialysis), clinical pathology, and radiology departments. Children with structural heart diseases were excluded from the study. All study populations were subjected to entire history taking, including aetiology, the onset of CKD, duration of hemodialysis, cardiac symptoms, medications, addition to routine and specific laboratory investigations, and radiological investigation that assessed the intimal medial thickness IMT and the peak systolic velocity (PSV)of the main arteries. Written consent was obtained from the participating parents in adherence to the ethical committee guidelines, Faculty of Medicine (for Girls), Cairo, AL-Azhar University, with ID no. 2334.</p>
   <p>Laboratory investigations</p>
   <p>Sampling</p>
   <p>Blood samples were collected during the mid-week dialysis session after a 12-hour overnight fast. The blood was drawn into three tubes using a vacuum system: one with EDTA and two gel vacuum tubes. An EDTA tube was used to analyze the CBC on the automated cell counter Swelab alpha. In contrast, one gel tube was used to measure urea, creatinine, calcium, phosphorous, potassium, cholesterol, and triglyceride levels using a Cobas C311 chemistry autoanalyzer (Roche Diagnostics).</p>
   <p>The second gel tube was centrifuged, and the serum was separated into two tubes. After careful labelling, it was stored at −20 until the DKK and Sclerostin assays.</p>
   <p>
    <xref ref-type="bibr" rid="scirp.136449-"></xref>Dickkopf levels were measured in the serum using ELISA with Fine Test kits. Samples were added to wells coated with a specific antibody, followed by incubation with biotin-labelled antibodies and an HRP conjugate. TMB substrate was added to create a blue colour in wells containing Dickkopf.1. After stopping the reaction with sulfuric acid and measuring the optical density at 450 nm; the results were calculated using a standard curve (<xref ref-type="bibr" rid="scirp.136449-https://www.fn-test.com/product/em0067/">
     https://www.fn-test.com/product/em0067/
    </xref>).</p>
   <p>Quantitative determination of the serum sclerostin concentration was performed using ELISA. The kits were delivered by Glory Bioscience (www. glorybioscience.com). In a microtiter plate, samples were added to wells coated with antibodies specific to sclerostin (SOST), incubated with SOST antibody and labelled HRP to form an antibody-antigen-enzyme-antibody complex. The wells were washed to remove non-specific complexes, and TMB substrate solution was added. The TMB substrate became blue in the HRP enzyme-catalyzed wells. The reaction was terminated by adding a stop solution, and the colour change was measured at a wavelength of 450 nm. The concentration of SOST in the samples was determined by comparing the (OD)cal density O.D. of the samples to the standard curve.</p>
   <p><u>Radiological investigations:</u></p>
   <p>Doppler ultrasound was used to measure the intimal medial thickness and peak systolic velocity of the main arteries, including the carotid, femoral, and ulnar arteries, using our university hospital’s “Esaote MyLab 50 Xvision” apparatus.</p>
   <p><u>Intimal medial thickness assessment</u><u>:</u></p>
   <p>The inner lining thickness of the carotid, femoral, and ulnar arteries was measured using grey-scale ultrasound with a 7.5 MHz probe. Patients were examined while lying down with their heads slightly tilted to the side for carotid measurements. For femoral measurements, the groin and abdominal area were exposed. The intima-media thickness was determined as the distance between the leading edge of the lumen-intima interface and the media-adventitia interface on the artery’s far wall <xref ref-type="bibr" rid="scirp.136449-20">
     [20]
    </xref>.</p>
   <p><u>Peak systolic velocity</u><u> (</u><u>PSV</u><u>)</u></p>
   <p>The peak systolic velocity (PSV) was measured using grayscale ultrasound with a 7.5 MHz probe. Patients were examined while lying down. The groin area was evaluated for femoral PSV, the neck was tilted to one side for carotid PSV, and the ulnar artery of the upper limb was assessed. Gel was applied to the examination area, and femoral arteries were examined longitudinally using a 7.5 MHz probe. Doppler examination included B-mode, colour mode, pulse wave, and peak systolic velocity measurements.</p>
   <p>Statistical analysis</p>
   <p>Data were collected, revised, coded, and entered into the Statistical Package for Social Science (IBM SPSS) version 27 by IBM in the USA. Qualitative data were presented as numbers and percentages. In contrast, quantitative data were presented as mean, standard deviations, and ranges when their distribution was parametric and as median with interquartile ranges(IQR) when their distribution was nonparametric. The comparison between two groups with qualitative data was done using the Chi-square test and Fisher exact test instead of the Chi-square test when the expected count in any cell was less than 5.</p>
   <p>The comparison between two independent groups with quantitative data was done using an Independent t-test when the data were parametric and a Mann-Whitney test when the data were non-parametric. Spearman correlation coefficients were used to assess the relation between two studied parameters in the same group.</p>
   <p>When the data were nonparametric, Spearman correlation coefficients were used to assess the relation between two studied parameters in the same group.</p>
   <p>The receiver operating characteristic (ROC) curve was used to determine the best cut-off point based on sensitivity and specificity. Regarding probability values, it was explicitly stated that P &gt; 0.05 was considered non-significant, while P &lt; 0.05 was deemed significant.</p>
   <p>The results</p>
   <p>
    <xref ref-type="table" rid="table1">
     Table 1
    </xref> compares patients and their controls, revealing a significant increase in systolic and diastolic blood pressure, cholesterol, triglyceride, urea, creatinine, PTH, phosphate, and CRP levels in the hemodialysis group compared to their controls. Additionally, platelet counts were higher in the patients than in their controls. The same table shows a significant increase in sclerostin and DKK1 in the hemodialysis group compared to their controls. Meanwhile, there was a substantial decrease in the haemoglobin, weight, and height z score in the patients when compared to their controls.</p>
   <p>
    <xref ref-type="table" rid="table2">
     Table 2
    </xref> shows that the most common causes of CKD in the patient’s group are acquired in 15 (37.5%), congenital in 12 (30%), and unknown in 11 (27.5), followed by hereditary causes in 2 (5%).</p>
   <p>
    <xref ref-type="table" rid="table3">
     Table 3
    </xref> compares the two groups (hemodialysis patients and controls) regarding the intima-media thickness (IMT) and peak systolic velocity (PSV) of the main arteries. IMT of the carotid, ulnar, and femoral arteries was significantly higher</p>
   <table-wrap id="table1">
    <label>
     <xref ref-type="table" rid="table1">
      Table 1
     </xref></label>
    <caption>
     <title>
      <xref ref-type="bibr" rid="scirp.136449-"></xref>Table 1. The clinical and laboratory data of the patients and their corresponding control group.</title>
    </caption>
    <table class="MsoTableGrid custom-table" border="0" cellspacing="0" cellpadding="0"> 
     <tr> 
      <td class="custom-bottom-td custom-top-td acenter" width="21.87%" colspan="2"><p style="text-align:center">Variable</p></td> 
      <td class="custom-bottom-td custom-top-td acenter" width="22.93%"><p style="text-align:center">Control group</p><p style="text-align:center">No. = 40</p><p style="text-align:center">Mean ± SD</p></td> 
      <td class="custom-bottom-td custom-top-td acenter" width="29.09%"><p style="text-align:center">Patients group</p><p style="text-align:center">No. = 40</p><p style="text-align:center">Mean ± SD</p></td> 
      <td class="custom-bottom-td custom-top-td acenter" width="14.11%"><p style="text-align:center">Test value</p></td> 
      <td class="custom-bottom-td custom-top-td acenter" width="12.00%"><p style="text-align:center">P-value</p></td> 
     </tr> 
     <tr> 
      <td class="custom-top-td acenter" width="21.87%" colspan="2"><p style="text-align:center">Age (years)</p></td> 
      <td class="custom-top-td acenter" width="22.93%"><p style="text-align:center">10.60 ± 2.98</p></td> 
      <td class="custom-top-td acenter" width="29.09%"><p style="text-align:center">11.98 ± 3.39</p></td> 
      <td class="custom-top-td acenter" width="14.11%"><p style="text-align:center">1.929</p></td> 
      <td class="custom-top-td acenter" width="12.00%"><p style="text-align:center">0.057</p></td> 
     </tr> 
     <tr> 
      <td class="acenter" width="21.87%" colspan="2"><p style="text-align:center">SBP (mmHg)</p></td> 
      <td class="acenter" width="22.93%"><p style="text-align:center">101.75 ± 7.89</p></td> 
      <td class="acenter" width="29.09%"><p style="text-align:center">131.0 ± 13.92</p></td> 
      <td class="acenter" width="14.11%"><p style="text-align:center">−11.560</p></td> 
      <td class="acenter" width="12.00%"><p style="text-align:center">0.001</p></td> 
     </tr> 
     <tr> 
      <td class="acenter" width="21.87%" colspan="2"><p style="text-align:center">DBP (mmHg)</p></td> 
      <td class="acenter" width="22.93%"><p style="text-align:center">61.38 ± 6.20</p></td> 
      <td class="acenter" width="29.09%"><p style="text-align:center">83.63 ± 9.13</p></td> 
      <td class="acenter" width="14.11%"><p style="text-align:center">−12.753</p></td> 
      <td class="acenter" width="12.00%"><p style="text-align:center">0.001</p></td> 
     </tr> 
     <tr> 
      <td class="acenter" width="21.87%" colspan="2"><p style="text-align:center">TLCX 10<sup>3</sup>/UL</p></td> 
      <td class="acenter" width="22.93%"><p style="text-align:center">7.72 ± 1.30</p></td> 
      <td class="acenter" width="29.09%"><p style="text-align:center">6.61 ± 2.31</p></td> 
      <td class="acenter" width="14.11%"><p style="text-align:center">2.655</p></td> 
      <td class="acenter" width="12.00%"><p style="text-align:center">0.01</p></td> 
     </tr> 
     <tr> 
      <td class="acenter" width="21.87%" colspan="2"><p style="text-align:center">RBCsX 10<sup>6</sup>/UL</p></td> 
      <td class="acenter" width="22.93%"><p style="text-align:center">4.74 ± 0.37</p></td> 
      <td class="acenter" width="29.09%"><p style="text-align:center">3.51 ± 0.63</p></td> 
      <td class="acenter" width="14.11%"><p style="text-align:center">10.669</p></td> 
      <td class="acenter" width="12.00%"><p style="text-align:center">0.001</p></td> 
     </tr> 
     <tr> 
      <td class="acenter" width="21.87%" colspan="2"><p style="text-align:center">Hb(gm/dl)</p></td> 
      <td class="acenter" width="22.93%"><p style="text-align:center">12.00 ± 0.86</p></td> 
      <td class="acenter" width="29.09%"><p style="text-align:center">9.46 ± 1.85</p></td> 
      <td class="acenter" width="14.11%"><p style="text-align:center">7.911</p></td> 
      <td class="acenter" width="12.00%"><p style="text-align:center">0.001</p></td> 
     </tr> 
     <tr> 
      <td class="acenter" width="21.87%" colspan="2"><p style="text-align:center">Hct%</p></td> 
      <td class="acenter" width="22.93%"><p style="text-align:center">36.46 ± 2.50</p></td> 
      <td class="acenter" width="29.09%"><p style="text-align:center">28.61 ± 5.75</p></td> 
      <td class="acenter" width="14.11%"><p style="text-align:center">7.922</p></td> 
      <td class="acenter" width="12.00%"><p style="text-align:center">0.001</p></td> 
     </tr> 
     <tr> 
      <td class="acenter" width="21.87%" colspan="2"><p style="text-align:center">Platelet 10<sup>3</sup>/UL</p></td> 
      <td class="acenter" width="22.93%"><p style="text-align:center">±79.96224</p></td> 
      <td class="acenter" width="29.09%"><p style="text-align:center">291.78 ± 54.88</p></td> 
      <td class="acenter" width="14.11%"><p style="text-align:center">4.377</p></td> 
      <td class="acenter" width="12.00%"><p style="text-align:center">0.001</p></td> 
     </tr> 
     <tr> 
      <td class="acenter" width="21.87%" colspan="2"><p style="text-align:center">Ca(mg/dl)</p></td> 
      <td class="acenter" width="22.93%"><p style="text-align:center">9.61 ± 2.31</p></td> 
      <td class="acenter" width="29.09%"><p style="text-align:center">8.46 ± 2.55</p></td> 
      <td class="acenter" width="14.11%"><p style="text-align:center">1.543</p></td> 
      <td class="acenter" width="12.00%"><p style="text-align:center">0.127</p></td> 
     </tr> 
     <tr> 
      <td class="acenter" width="21.87%" colspan="2"><p style="text-align:center">Ph(mg/dl)</p></td> 
      <td class="acenter" width="22.93%"><p style="text-align:center">3.51 ± 0.63</p></td> 
      <td class="acenter" width="29.09%"><p style="text-align:center">5.44 ± 2.18</p></td> 
      <td class="acenter" width="14.11%"><p style="text-align:center">−3.100</p></td> 
      <td class="acenter" width="12.00%"><p style="text-align:center">0.003</p></td> 
     </tr> 
     <tr> 
      <td class="acenter" width="21.87%" colspan="2"><p style="text-align:center">Cholesterol mg/dl</p></td> 
      <td class="acenter" width="22.93%"><p style="text-align:center">101.95 ± 11.79</p></td> 
      <td class="acenter" width="29.09%"><p style="text-align:center">168.93 ± 32.41</p></td> 
      <td class="acenter" width="14.11%"><p style="text-align:center">−12.281</p></td> 
      <td class="acenter" width="12.00%"><p style="text-align:center">0.001</p></td> 
     </tr> 
     <tr> 
      <td class="acenter" width="21.87%" colspan="2"><p style="text-align:center">Triglyceride mg/dl</p></td> 
      <td class="acenter" width="22.93%"><p style="text-align:center">83.38 ± 17.44</p></td> 
      <td class="acenter" width="29.09%"><p style="text-align:center">175.33 ± 46.46</p></td> 
      <td class="acenter" width="14.11%"><p style="text-align:center">−11.718</p></td> 
      <td class="acenter" width="12.00%"><p style="text-align:center">0.001</p></td> 
     </tr> 
     <tr> 
      <td class="custom-bottom-td acenter" width="21.87%" colspan="2"><p style="text-align:center">Urea mg/dl</p></td> 
      <td class="custom-bottom-td acenter" width="22.93%"><p style="text-align:center">26.43 ± 6.97</p></td> 
      <td class="custom-bottom-td acenter" width="29.09%"><p style="text-align:center">113.9 ± 36.26</p></td> 
      <td class="custom-bottom-td acenter" width="14.11%"><p style="text-align:center">112.97</p></td> 
      <td class="custom-bottom-td acenter" width="12.00%"><p style="text-align:center">0.001</p></td> 
     </tr> 
     <tr> 
      <td class="custom-bottom-td custom-top-td acenter" width="21.87%" colspan="2"><p style="text-align:center">Variable</p></td> 
      <td class="custom-bottom-td custom-top-td acenter" width="22.93%"><p style="text-align:center">Median (IQR)</p></td> 
      <td class="custom-bottom-td custom-top-td acenter" width="29.09%"><p style="text-align:center">Median (IQR)</p></td> 
      <td class="custom-bottom-td custom-top-td acenter" width="14.11%"><p style="text-align:center">Test value</p></td> 
      <td class="custom-bottom-td custom-top-td acenter" width="12.00%"><p style="text-align:center">p</p></td> 
     </tr> 
     <tr> 
      <td class="custom-top-td acenter" width="21.73%"><p style="text-align:center">Z-score: Wt</p></td> 
      <td class="custom-top-td acenter" width="23.07%" colspan="2"><p style="text-align:center">0.29 (−0.48 - 1.30)</p></td> 
      <td class="custom-top-td acenter" width="29.09%"><p style="text-align:center">−0.56 (−1.00 - 0.22)</p></td> 
      <td class="custom-top-td acenter" width="14.11%"><p style="text-align:center">3.137</p></td> 
      <td class="custom-top-td acenter" width="12.00%"><p style="text-align:center">0.002</p></td> 
     </tr> 
     <tr> 
      <td class="acenter" width="21.73%"><p style="text-align:center">Z-score: Ht</p></td> 
      <td class="acenter" width="23.07%" colspan="2"><p style="text-align:center">0.55 (−0.18 - 1.13)</p></td> 
      <td class="acenter" width="29.09%"><p style="text-align:center">−0.43 (−1.24 - 0.30)</p></td> 
      <td class="acenter" width="14.11%"><p style="text-align:center">4.043</p></td> 
      <td class="acenter" width="12.00%"><p style="text-align:center">0.001</p></td> 
     </tr> 
     <tr> 
      <td class="acenter" width="21.73%"><p style="text-align:center">Z-score: BMI</p></td> 
      <td class="acenter" width="23.07%" colspan="2"><p style="text-align:center">−0.32 (−0.82 - 1.13)</p></td> 
      <td class="acenter" width="29.09%"><p style="text-align:center">−0.18 (−0.68 - 0.25)</p></td> 
      <td class="acenter" width="14.11%"><p style="text-align:center">0.720</p></td> 
      <td class="acenter" width="12.00%"><p style="text-align:center">0.474</p></td> 
     </tr> 
     <tr> 
      <td class="acenter" width="21.73%"><p style="text-align:center">CRP (mg/l)</p></td> 
      <td class="acenter" width="23.07%" colspan="2"><p style="text-align:center">3 (2 - 4)</p></td> 
      <td class="acenter" width="29.09%"><p style="text-align:center">12.5 (8 - 24)</p></td> 
      <td class="acenter" width="14.11%"><p style="text-align:center">−6.664</p></td> 
      <td class="acenter" width="12.00%"><p style="text-align:center">0.001</p></td> 
     </tr> 
     <tr> 
      <td class="acenter" width="21.73%"><p style="text-align:center">Creatinine(md/dl)</p></td> 
      <td class="acenter" width="23.07%" colspan="2"><p style="text-align:center">0.4 (0.25 - 0.50)</p></td> 
      <td class="acenter" width="29.09%"><p style="text-align:center">2.1 (1.65 - 3.20)</p></td> 
      <td class="acenter" width="14.11%"><p style="text-align:center">−7.704</p></td> 
      <td class="acenter" width="12.00%"><p style="text-align:center">0.001</p></td> 
     </tr> 
     <tr> 
      <td class="acenter" width="21.73%"><p style="text-align:center">PTH (pg/ml)</p></td> 
      <td class="acenter" width="23.07%" colspan="2"><p style="text-align:center">54.5 (44.5 - 63.0)</p></td> 
      <td class="acenter" width="29.09%"><p style="text-align:center">342.5 (173.5 - 714)</p></td> 
      <td class="acenter" width="14.11%"><p style="text-align:center">−7.430</p></td> 
      <td class="acenter" width="12.00%"><p style="text-align:center">0.001</p></td> 
     </tr> 
     <tr> 
      <td class="acenter" width="21.73%"><p style="text-align:center">Sclerostin (ng/ml)</p></td> 
      <td class="acenter" width="23.07%" colspan="2"><p style="text-align:center">0.28 (0.25 - 0.32)</p></td> 
      <td class="acenter" width="29.09%"><p style="text-align:center">1.17 (0.85 - 2.03)</p></td> 
      <td class="acenter" width="14.11%"><p style="text-align:center">−7.701</p></td> 
      <td class="acenter" width="12.00%"><p style="text-align:center">0.001</p></td> 
     </tr> 
     <tr> 
      <td class="custom-bottom-td acenter" width="21.73%"><p style="text-align:center">Dickkopf-1 (pg/ml).</p></td> 
      <td class="custom-bottom-td acenter" width="23.07%" colspan="2"><p style="text-align:center">1100 (880 - 1537.8)</p></td> 
      <td class="custom-bottom-td acenter" width="29.09%"><p style="text-align:center">2540.65 (2215.4 - 2909.2)</p></td> 
      <td class="custom-bottom-td acenter" width="14.11%"><p style="text-align:center">6.805</p></td> 
      <td class="custom-bottom-td acenter" width="12.00%"><p style="text-align:center">0.001</p></td> 
     </tr> 
    </table>
   </table-wrap>
   <p>SBP: systolic blood pressure; DBP: diastolic blood pressure; PTH: parathyroid hormone.</p>
   <p>
    <xref ref-type="bibr" rid="scirp.136449-"></xref></p>
   <table-wrap id="table2">
    <label>
     <xref ref-type="table" rid="table2">
      Table 2
     </xref></label>
    <caption>
     <title>
      <xref ref-type="bibr" rid="scirp.136449-"></xref>Table 2. Etiology of CKD of the study patients.</title>
    </caption>
    <table class="MsoTableGrid custom-table" border="0" cellspacing="0" cellpadding="0"> 
     <tr> 
      <td class="custom-bottom-td custom-top-td acenter" width="62.74%"><p style="text-align:center">1ry lesion of CKD</p></td> 
      <td class="custom-bottom-td custom-top-td acenter" width="37.26%"><p style="text-align:center">No.40</p><p style="text-align:center">No. (%)</p></td> 
     </tr> 
     <tr> 
      <td class="custom-top-td acenter" width="62.74%"><p style="text-align:center">Congenital</p></td> 
      <td class="custom-top-td acenter" width="37.26%"><p style="text-align:center">12 (30%)</p></td> 
     </tr> 
     <tr> 
      <td class="acenter" width="62.74%"><p style="text-align:center">Reflux nephropathy</p></td> 
      <td class="acenter" width="37.26%"><p style="text-align:center">5 (12.5%)</p></td> 
     </tr> 
     <tr> 
      <td class="acenter" width="62.74%"><p style="text-align:center">Posterior urethral valve</p></td> 
      <td class="acenter" width="37.26%"><p style="text-align:center">2 (5%)</p></td> 
     </tr> 
     <tr> 
      <td class="acenter" width="62.74%"><p style="text-align:center">Multicyclic dysplastic kidney</p></td> 
      <td class="acenter" width="37.26%"><p style="text-align:center">5 (12.5%)</p></td> 
     </tr> 
     <tr> 
      <td class="acenter" width="62.74%"><p style="text-align:center">Hereditary</p></td> 
      <td class="acenter" width="37.26%"><p style="text-align:center">2 (5%)</p></td> 
     </tr> 
     <tr> 
      <td class="custom-bottom-td acenter" width="62.74%"><p style="text-align:center">Joubert syndrome</p></td> 
      <td class="custom-bottom-td acenter" width="37.26%"><p style="text-align:center">2 (5%)</p></td> 
     </tr> 
     <tr> 
      <td class="acenter" width="62.74%"><p style="text-align:center">Acquired</p></td> 
      <td class="acenter" width="37.26%"><p style="text-align:center">15 (37.5%)</p></td> 
     </tr> 
     <tr> 
      <td class="acenter" width="62.74%"><p style="text-align:center">Focal segmental glomerulosclerosis</p></td> 
      <td class="acenter" width="37.26%"><p style="text-align:center">10 (25%)</p></td> 
     </tr> 
     <tr> 
      <td class="acenter" width="62.74%"><p style="text-align:center">Masango proliferative glomerulonephritis</p></td> 
      <td class="acenter" width="37.26%"><p style="text-align:center">2 (5%)</p></td> 
     </tr> 
     <tr> 
      <td class="acenter" width="62.74%"><p style="text-align:center">Interstitial nephritis</p></td> 
      <td class="acenter" width="37.26%"><p style="text-align:center">3 (7.5%)</p></td> 
     </tr> 
     <tr> 
      <td class="acenter" width="62.74%"><p style="text-align:center">Unknown</p></td> 
      <td class="acenter" width="37.26%"><p style="text-align:center">11 (27.5%)</p></td> 
     </tr> 
    </table>
   </table-wrap>
   <table-wrap id="table3">
    <label>
     <xref ref-type="table" rid="table3">
      Table 3
     </xref></label>
    <caption>
     <title>
      <xref ref-type="bibr" rid="scirp.136449-"></xref>Table 3. Comparison of IMT &amp; PSV of the main arteries between the patient group &amp; control group.</title>
    </caption>
    <table class="MsoTableGrid custom-table" border="0" cellspacing="0" cellpadding="0"> 
     <tr> 
      <td class="custom-bottom-td custom-top-td acenter" width="25.31%"><p style="text-align:center">IMT (cm)</p></td> 
      <td class="custom-bottom-td custom-top-td acenter" width="20.92%"><p style="text-align:center">Control group</p><p style="text-align:center">No. = 40</p><p style="text-align:center">Mean ± SD</p></td> 
      <td class="custom-bottom-td custom-top-td acenter" width="20.92%"><p style="text-align:center">Patients group</p><p style="text-align:center">No. = 40</p><p style="text-align:center">Mean ± SD</p></td> 
      <td class="custom-bottom-td custom-top-td acenter" width="13.46%"><p style="text-align:center">t-test</p></td> 
      <td class="custom-bottom-td custom-top-td acenter" width="19.38%"><p style="text-align:center">P-value</p></td> 
     </tr> 
     <tr> 
      <td class="custom-top-td acenter" width="25.31%"><p style="text-align:center">Carotid</p></td> 
      <td class="custom-top-td acenter" width="20.92%"><p style="text-align:center">0.05 ± 0.01</p></td> 
      <td class="custom-top-td acenter" width="20.92%"><p style="text-align:center">0.06 ± 0.02</p></td> 
      <td class="custom-top-td acenter" width="13.46%"><p style="text-align:center">−2.992</p></td> 
      <td class="custom-top-td acenter" width="19.38%"><p style="text-align:center">0.004</p></td> 
     </tr> 
     <tr> 
      <td class="acenter" width="25.31%"><p style="text-align:center">Ulnar</p></td> 
      <td class="acenter" width="20.92%"><p style="text-align:center">0.04 ± 0.01</p></td> 
      <td class="acenter" width="20.92%"><p style="text-align:center">0.05 ± 0.01</p></td> 
      <td class="acenter" width="13.46%"><p style="text-align:center">−3.800</p></td> 
      <td class="acenter" width="19.38%"><p style="text-align:center">0.001</p></td> 
     </tr> 
     <tr> 
      <td class="acenter" width="25.31%"><p style="text-align:center">Femoral</p></td> 
      <td class="acenter" width="20.92%"><p style="text-align:center">0.05 ± 0.01</p></td> 
      <td class="acenter" width="20.92%"><p style="text-align:center">0.07 ± 0.01</p></td> 
      <td class="acenter" width="13.46%"><p style="text-align:center">−6.616</p></td> 
      <td class="acenter" width="19.38%"><p style="text-align:center">0.001</p></td> 
     </tr> 
     <tr> 
      <td class="acenter" width="25.31%"><p style="text-align:center">Mean PSV cm/sec</p></td> 
      <td class="acenter" width="20.92%"><p style="text-align:center"></p></td> 
      <td class="acenter" width="20.92%"><p style="text-align:center"></p></td> 
      <td class="acenter" width="13.46%"><p style="text-align:center"></p></td> 
      <td class="acenter" width="19.38%"><p style="text-align:center"></p></td> 
     </tr> 
     <tr> 
      <td class="acenter" width="25.31%"><p style="text-align:center">Carotid</p></td> 
      <td class="acenter" width="20.92%"><p style="text-align:center">52.8 ± 8.16</p></td> 
      <td class="acenter" width="20.92%"><p style="text-align:center">47.35 ± 4.81</p></td> 
      <td class="acenter" width="13.46%"><p style="text-align:center">3.641</p></td> 
      <td class="acenter" width="19.38%"><p style="text-align:center">0.001</p></td> 
     </tr> 
     <tr> 
      <td class="acenter" width="25.31%"><p style="text-align:center">Ulnar</p></td> 
      <td class="acenter" width="20.92%"><p style="text-align:center">43.53 ± 6.26</p></td> 
      <td class="acenter" width="20.92%"><p style="text-align:center">38.8 ± 6.36</p></td> 
      <td class="acenter" width="13.46%"><p style="text-align:center">3.349</p></td> 
      <td class="acenter" width="19.38%"><p style="text-align:center">0.0003</p></td> 
     </tr> 
     <tr> 
      <td class="custom-bottom-td acenter" width="25.31%"><p style="text-align:center">Femoral</p></td> 
      <td class="custom-bottom-td acenter" width="20.92%"><p style="text-align:center">60 ± 8.54</p></td> 
      <td class="custom-bottom-td acenter" width="20.92%"><p style="text-align:center">57.43 ± 9.88</p></td> 
      <td class="custom-bottom-td acenter" width="13.46%"><p style="text-align:center">1.247</p></td> 
      <td class="custom-bottom-td acenter" width="19.38%"><p style="text-align:center">0.10806</p></td> 
     </tr> 
    </table>
   </table-wrap>
   <p>IMT: intimal medial thickness; PSV: peak systolic velocity.</p>
   <p>in the hemodialysis group than in the control group. Additionally, the PSV in the carotid and ulnar arteries was considerably lower in the hemodialysis group than in the control group.</p>
   <p>
    <xref ref-type="table" rid="table4">
     Table 4
    </xref> shows that sclerostin was significantly correlated with blood pressure, platelet count, PTH, cholesterol, triglyceride, and CRP levels. Moreover, sclerostin was found to have a significant correlation with the intima-media thickness (IMT) of the carotid, ulnar, and femoral arteries. However, there was a significant negative correlation between sclerostin level and height, serum calcium level, and peak systolic velocity (PSV) of the main arteries.</p>
   <p>Similarly, the same table also reveals a significant correlation between Dickkopf-1. and age, blood pressure, platelets, cholesterol, triglycerides, and PTH levels. Additionally, it showed a significant correlation with the IMT of the main vessels’ carotid, ulnar, and femoral arteries, with a negative correlation with the height and PSV of the main arteries.</p>
   <p>
    <xref ref-type="bibr" rid="scirp.136449-"></xref><xref ref-type="table" rid="table5">
     Table 5
    </xref> displays the optimal cutoff point, sensitivity, and specificity of sclerostin and Dickkopf-1 in predicting cardiovascular risk in children undergoing maintenance hemodialysis. The sensitivity and specificity were 100.0%, 87.50%, 100.0%, and 97%, respectively.</p>
   <p>
    <xref ref-type="fig" rid="fig1">
     Figure 1
    </xref> depicts the cIMT of one patient group in the study, with a carotid intimal medial thickness of 0.04 cm.</p>
   <table-wrap id="table4">
    <label>
     <xref ref-type="table" rid="table4">
      Table 4
     </xref></label>
    <caption>
     <title>
      <xref ref-type="bibr" rid="scirp.136449-"></xref>Table 4. Sclerostin and Dickkopf-1 level correlation with the study groups’ clinical, laboratory and radiological data</title>
    </caption>
    <table class="MsoTableGrid custom-table" border="0" cellspacing="0" cellpadding="0"> 
     <tr> 
      <td rowspan="2" class="custom-top-td acenter" width="36.24%"><p style="text-align:center">Variable</p></td> 
      <td class="custom-bottom-td custom-top-td acenter" width="31.88%" colspan="2"><p style="text-align:center">Sclerostin (ng/ml)</p></td> 
      <td class="custom-bottom-td custom-top-td acenter" width="31.88%" colspan="2"><p style="text-align:center">Dickkopf-1 (pg/ml)</p></td> 
     </tr> 
     <tr> 
      <td class="custom-bottom-td custom-top-td acenter" width="14.86%"><p style="text-align:center">r</p></td> 
      <td class="custom-bottom-td custom-top-td acenter" width="17.02%"><p style="text-align:center">p-value</p></td> 
      <td class="custom-bottom-td custom-top-td acenter" width="14.86%"><p style="text-align:center">r</p></td> 
      <td class="custom-bottom-td custom-top-td acenter" width="17.02%"><p style="text-align:center">p-value</p></td> 
     </tr> 
     <tr> 
      <td class="custom-top-td acenter" width="36.24%"><p style="text-align:center">Sclerostin (ng/ml)</p></td> 
      <td class="custom-top-td acenter" width="14.86%"><p style="text-align:center">1.000</p></td> 
      <td class="custom-top-td acenter" width="17.02%"><p style="text-align:center"></p></td> 
      <td class="custom-top-td acenter" width="14.86%"><p style="text-align:center">0.574</p></td> 
      <td class="custom-top-td acenter" width="17.02%"><p style="text-align:center">0.001</p></td> 
     </tr> 
     <tr> 
      <td class="acenter" width="36.24%"><p style="text-align:center">Dickkopf-1</p></td> 
      <td class="acenter" width="14.86%"><p style="text-align:center">0.574</p></td> 
      <td class="acenter" width="17.02%"><p style="text-align:center">0.001</p></td> 
      <td class="acenter" width="14.86%"><p style="text-align:center"></p></td> 
      <td class="acenter" width="17.02%"><p style="text-align:center"></p></td> 
     </tr> 
     <tr> 
      <td class="acenter" width="36.24%"><p style="text-align:center">Age</p></td> 
      <td class="acenter" width="14.86%"><p style="text-align:center">0.298</p></td> 
      <td class="acenter" width="17.02%"><p style="text-align:center">0.062</p></td> 
      <td class="acenter" width="14.86%"><p style="text-align:center">0.349</p></td> 
      <td class="acenter" width="17.02%"><p style="text-align:center">0.027</p></td> 
     </tr> 
     <tr> 
      <td class="acenter" width="36.24%"><p style="text-align:center">Ht (cm)</p></td> 
      <td class="acenter" width="14.86%"><p style="text-align:center">−0.486</p></td> 
      <td class="acenter" width="17.02%"><p style="text-align:center">0.001</p></td> 
      <td class="acenter" width="14.86%"><p style="text-align:center">−0.350</p></td> 
      <td class="acenter" width="17.02%"><p style="text-align:center">0.027</p></td> 
     </tr> 
     <tr> 
      <td class="acenter" width="36.24%"><p style="text-align:center">BMI</p></td> 
      <td class="acenter" width="14.86%"><p style="text-align:center">0.077</p></td> 
      <td class="acenter" width="17.02%"><p style="text-align:center">0.636</p></td> 
      <td class="acenter" width="14.86%"><p style="text-align:center">0.035</p></td> 
      <td class="acenter" width="17.02%"><p style="text-align:center">0.830</p></td> 
     </tr> 
     <tr> 
      <td class="acenter" width="36.24%"><p style="text-align:center">SBP (mmHg)</p></td> 
      <td class="acenter" width="14.86%"><p style="text-align:center">0.253</p></td> 
      <td class="acenter" width="17.02%"><p style="text-align:center">0.115</p></td> 
      <td class="acenter" width="14.86%"><p style="text-align:center">0.415</p></td> 
      <td class="acenter" width="17.02%"><p style="text-align:center">0.008</p></td> 
     </tr> 
     <tr> 
      <td class="acenter" width="36.24%"><p style="text-align:center">DBP (mmHg)</p></td> 
      <td class="acenter" width="14.86%"><p style="text-align:center">0.425</p></td> 
      <td class="acenter" width="17.02%"><p style="text-align:center">0.006</p></td> 
      <td class="acenter" width="14.86%"><p style="text-align:center">0.346</p></td> 
      <td class="acenter" width="17.02%"><p style="text-align:center">0.029</p></td> 
     </tr> 
     <tr> 
      <td class="acenter" width="36.24%"><p style="text-align:center">TLCX 10<sup>3</sup>/UL</p></td> 
      <td class="acenter" width="14.86%"><p style="text-align:center">−0.082</p></td> 
      <td class="acenter" width="17.02%"><p style="text-align:center">0.615</p></td> 
      <td class="acenter" width="14.86%"><p style="text-align:center">−0.009</p></td> 
      <td class="acenter" width="17.02%"><p style="text-align:center">0.954</p></td> 
     </tr> 
     <tr> 
      <td class="acenter" width="36.24%"><p style="text-align:center">RBCsX 10<sup>6</sup>/UL</p></td> 
      <td class="acenter" width="14.86%"><p style="text-align:center">0.194</p></td> 
      <td class="acenter" width="17.02%"><p style="text-align:center">0.230</p></td> 
      <td class="acenter" width="14.86%"><p style="text-align:center">0.135</p></td> 
      <td class="acenter" width="17.02%"><p style="text-align:center">0.408</p></td> 
     </tr> 
     <tr> 
      <td class="acenter" width="36.24%"><p style="text-align:center">Hb (gm/dl)</p></td> 
      <td class="acenter" width="14.86%"><p style="text-align:center">0.185</p></td> 
      <td class="acenter" width="17.02%"><p style="text-align:center">0.252</p></td> 
      <td class="acenter" width="14.86%"><p style="text-align:center">0.171</p></td> 
      <td class="acenter" width="17.02%"><p style="text-align:center">0.291</p></td> 
     </tr> 
     <tr> 
      <td class="acenter" width="36.24%"><p style="text-align:center">Hct %</p></td> 
      <td class="acenter" width="14.86%"><p style="text-align:center">0.179</p></td> 
      <td class="acenter" width="17.02%"><p style="text-align:center">0.270</p></td> 
      <td class="acenter" width="14.86%"><p style="text-align:center">0.057</p></td> 
      <td class="acenter" width="17.02%"><p style="text-align:center">0.727</p></td> 
     </tr> 
     <tr> 
      <td class="acenter" width="36.24%"><p style="text-align:center">Platelet 10<sup>3</sup> /UL</p></td> 
      <td class="acenter" width="14.86%"><p style="text-align:center">0.440</p></td> 
      <td class="acenter" width="17.02%"><p style="text-align:center">0.004</p></td> 
      <td class="acenter" width="14.86%"><p style="text-align:center">0.362</p></td> 
      <td class="acenter" width="17.02%"><p style="text-align:center">0.022</p></td> 
     </tr> 
     <tr> 
      <td class="acenter" width="36.24%"><p style="text-align:center">Urea (mg/dl)</p></td> 
      <td class="acenter" width="14.86%"><p style="text-align:center">−0.226</p></td> 
      <td class="acenter" width="17.02%"><p style="text-align:center">0.161</p></td> 
      <td class="acenter" width="14.86%"><p style="text-align:center">−0.182</p></td> 
      <td class="acenter" width="17.02%"><p style="text-align:center">0.261</p></td> 
     </tr> 
     <tr> 
      <td class="acenter" width="36.24%"><p style="text-align:center">Creatinine (mg/dl)</p></td> 
      <td class="acenter" width="14.86%"><p style="text-align:center">−0.189</p></td> 
      <td class="acenter" width="17.02%"><p style="text-align:center">0.243</p></td> 
      <td class="acenter" width="14.86%"><p style="text-align:center">−0.163</p></td> 
      <td class="acenter" width="17.02%"><p style="text-align:center">0.316</p></td> 
     </tr> 
     <tr> 
      <td class="acenter" width="36.24%"><p style="text-align:center">Ca (mg/dl)</p></td> 
      <td class="acenter" width="14.86%"><p style="text-align:center">−0.581</p></td> 
      <td class="acenter" width="17.02%"><p style="text-align:center">0.001</p></td> 
      <td class="acenter" width="14.86%"><p style="text-align:center">−0.311</p></td> 
      <td class="acenter" width="17.02%"><p style="text-align:center">0.051</p></td> 
     </tr> 
     <tr> 
      <td class="acenter" width="36.24%"><p style="text-align:center">Ph (mg/dl)</p></td> 
      <td class="acenter" width="14.86%"><p style="text-align:center">−0.140</p></td> 
      <td class="acenter" width="17.02%"><p style="text-align:center">0.389</p></td> 
      <td class="acenter" width="14.86%"><p style="text-align:center">−0.125</p></td> 
      <td class="acenter" width="17.02%"><p style="text-align:center">0.441</p></td> 
     </tr> 
     <tr> 
      <td class="acenter" width="36.24%"><p style="text-align:center">ALP (U/L)</p></td> 
      <td class="acenter" width="14.86%"><p style="text-align:center">−0.131</p></td> 
      <td class="acenter" width="17.02%"><p style="text-align:center">0.420</p></td> 
      <td class="acenter" width="14.86%"><p style="text-align:center">0.071</p></td> 
      <td class="acenter" width="17.02%"><p style="text-align:center">0.664</p></td> 
     </tr> 
     <tr> 
      <td class="acenter" width="36.24%"><p style="text-align:center">PTH (pg/ml)</p></td> 
      <td class="acenter" width="14.86%"><p style="text-align:center">0.631</p></td> 
      <td class="acenter" width="17.02%"><p style="text-align:center">0.001</p></td> 
      <td class="acenter" width="14.86%"><p style="text-align:center">0.406</p></td> 
      <td class="acenter" width="17.02%"><p style="text-align:center">0.009</p></td> 
     </tr> 
     <tr> 
      <td class="acenter" width="36.24%"><p style="text-align:center">Cholesterol (mg/dl)</p></td> 
      <td class="acenter" width="14.86%"><p style="text-align:center">0.423</p></td> 
      <td class="acenter" width="17.02%"><p style="text-align:center">0.007</p></td> 
      <td class="acenter" width="14.86%"><p style="text-align:center">0.093</p></td> 
      <td class="acenter" width="17.02%"><p style="text-align:center">0.570</p></td> 
     </tr> 
     <tr> 
      <td class="acenter" width="36.24%"><p style="text-align:center">Triglyceride (mg/dl)</p></td> 
      <td class="acenter" width="14.86%"><p style="text-align:center">0.514</p></td> 
      <td class="acenter" width="17.02%"><p style="text-align:center">0.001</p></td> 
      <td class="acenter" width="14.86%"><p style="text-align:center">0.246</p></td> 
      <td class="acenter" width="17.02%"><p style="text-align:center">0.126</p></td> 
     </tr> 
     <tr> 
      <td class="acenter" width="36.24%"><p style="text-align:center">CRP (mg/l)</p></td> 
      <td class="acenter" width="14.86%"><p style="text-align:center">0.628</p></td> 
      <td class="acenter" width="17.02%"><p style="text-align:center">0.001</p></td> 
      <td class="acenter" width="14.86%"><p style="text-align:center">0.378</p></td> 
      <td class="acenter" width="17.02%"><p style="text-align:center">0.016</p></td> 
     </tr> 
     <tr> 
      <td class="acenter" width="36.24%"><p style="text-align:center">Carotid IMT (cm)</p></td> 
      <td class="acenter" width="14.86%"><p style="text-align:center">0.663</p></td> 
      <td class="acenter" width="17.02%"><p style="text-align:center">0.001</p></td> 
      <td class="acenter" width="14.86%"><p style="text-align:center">0.516</p></td> 
      <td class="acenter" width="17.02%"><p style="text-align:center">0.001</p></td> 
     </tr> 
     <tr> 
      <td class="acenter" width="36.24%"><p style="text-align:center">Ulnar IMT (cm)</p></td> 
      <td class="acenter" width="14.86%"><p style="text-align:center">0.437</p></td> 
      <td class="acenter" width="17.02%"><p style="text-align:center">0.005</p></td> 
      <td class="acenter" width="14.86%"><p style="text-align:center">0.319</p></td> 
      <td class="acenter" width="17.02%"><p style="text-align:center">0.045</p></td> 
     </tr> 
     <tr> 
      <td class="custom-bottom-td acenter" width="36.24%"><p style="text-align:center">Femoral IMT (cm)</p></td> 
      <td class="custom-bottom-td acenter" width="14.86%"><p style="text-align:center">0.410</p></td> 
      <td class="custom-bottom-td acenter" width="17.02%"><p style="text-align:center">0.009</p></td> 
      <td class="custom-bottom-td acenter" width="14.86%"><p style="text-align:center">0.355</p></td> 
      <td class="custom-bottom-td acenter" width="17.02%"><p style="text-align:center">0.024</p></td> 
     </tr> 
    </table>
   </table-wrap>
   <p>IMT: intimal medial thickness; BMI: body mass index; PTH: parathyroid hormone: ALP: alkaline phosphatase.</p>
   <table-wrap id="table5">
    <label>
     <xref ref-type="table" rid="table5">
      Table 5
     </xref></label>
    <caption>
     <title>
      <xref ref-type="bibr" rid="scirp.136449-"></xref>Table 5. The best cut-off points for sensitivity and specificity of sclerostin and Dickkopf-1 in predicting cardiovascular risk in children on maintenance hemodialysis.</title>
    </caption>
    <table class="MsoTableGrid custom-table" border="0" cellspacing="0" cellpadding="0"> 
     <tr> 
      <td class="custom-bottom-td custom-top-td acenter" width="24.69%"><p style="text-align:center">Parameters</p></td> 
      <td class="custom-bottom-td custom-top-td acenter" width="11.53%"><p style="text-align:center">Cut off point</p></td> 
      <td class="custom-bottom-td custom-top-td acenter" width="9.38%"><p style="text-align:center">AUC</p></td> 
      <td class="custom-bottom-td custom-top-td acenter" width="15.68%"><p style="text-align:center">Sensitivity</p></td> 
      <td class="custom-bottom-td custom-top-td acenter" width="15.63%"><p style="text-align:center">Specificity</p></td> 
      <td class="custom-bottom-td custom-top-td acenter" width="11.55%"><p style="text-align:center">+PV</p></td> 
      <td class="custom-bottom-td custom-top-td acenter" width="11.55%"><p style="text-align:center">−PV</p></td> 
     </tr> 
     <tr> 
      <td class="custom-top-td acenter" width="24.69%"><p style="text-align:center">Sclerostin (ng/ml)</p></td> 
      <td class="custom-top-td acenter" width="11.53%"><p style="text-align:center">&gt;0.38</p></td> 
      <td class="custom-top-td acenter" width="9.38%"><p style="text-align:center">1.000</p></td> 
      <td class="custom-top-td acenter" width="15.68%"><p style="text-align:center">100.0%</p></td> 
      <td class="custom-top-td acenter" width="15.63%"><p style="text-align:center">100.0%</p></td> 
      <td class="custom-top-td acenter" width="11.55%"><p style="text-align:center">100.0%</p></td> 
      <td class="custom-top-td acenter" width="11.55%"><p style="text-align:center">100.0%</p></td> 
     </tr> 
     <tr> 
      <td class="custom-bottom-td acenter" width="24.69%"><p style="text-align:center">Dickkopf-1 (pg/ml)</p></td> 
      <td class="custom-bottom-td acenter" width="11.53%"><p style="text-align:center">&gt;1851</p></td> 
      <td class="custom-bottom-td acenter" width="9.38%"><p style="text-align:center">0.945</p></td> 
      <td class="custom-bottom-td acenter" width="15.68%"><p style="text-align:center">87.50%</p></td> 
      <td class="custom-bottom-td acenter" width="15.63%"><p style="text-align:center">97.44%</p></td> 
      <td class="custom-bottom-td acenter" width="11.55%"><p style="text-align:center">97.2%</p></td> 
      <td class="custom-bottom-td acenter" width="11.55%"><p style="text-align:center">88.4%</p></td> 
     </tr> 
    </table>
   </table-wrap>
   <fig id="fig1" position="float">
    <label>Figure 1</label>
    <caption>
     <title>Figure 1. Carotid intimal medial thickness in one of the study patient group.</title>
    </caption>
    <graphic mimetype="image" position="float" xlink:type="simple" xlink:href="https://html.scirp.org/file/2070628-rId14.jpeg?20240930044954" />
   </fig>
   <fig id="fig2" position="float">
    <label>Figure 2</label>
    <caption>
     <title>
      <xref ref-type="bibr" rid="scirp.136449-"></xref>Figure 2. The mean PSV of the carotid artery in one of the study patient group.</title>
    </caption>
    <graphic mimetype="image" position="float" xlink:type="simple" xlink:href="https://html.scirp.org/file/2070628-rId15.jpeg?20240930044954" />
   </fig>
   <p>
    <xref ref-type="fig" rid="fig2">
     Figure 2
    </xref> shows that one of the study patients’ groups, PSV, is 50 cm/sec.</p>
   <p>
    <xref ref-type="fig" rid="fig3">
     Figure 3
    </xref> shows a significant positive correlation between carotid IMT and sclerostin serum levels.</p>
   <p>
    <xref ref-type="fig" rid="fig4">
     Figure 4
    </xref> shows a significant positive correlation between the carotid IMT and Dickkopf-1.</p>
   <p>
    <xref ref-type="fig" rid="fig5">
     Figure 5
    </xref> shows the specificity and sensitivity of sclerostin and Dickkopf-1 Serum levels in predicting cardiovascular risk in pediatric patients on regular hemodialysis: 100.0%, 87.50%, 100.0%, and 97%, respectively.</p>
  </sec><sec id="s3">
   <title>3. Discussion</title>
   <p>This case-control study is the first to describe the impact of sclerostin and Dickkopf-1 on vascular calcification (VC) in children undergoing hemodialysis by</p>
   <fig id="fig3" position="float">
    <label>Figure 3</label>
    <caption>
     <title>Figure 3. Correlation between the carotid IMT and sclerostin serum level.</title>
    </caption>
    <graphic mimetype="image" position="float" xlink:type="simple" xlink:href="https://html.scirp.org/file/2070628-rId16.jpeg?20240930044955" />
   </fig>
   <fig id="fig4" position="float">
    <label>Figure 4</label>
    <caption>
     <title>Figure 4. Correlation between the carotid IMT and Dickkopf-1 (DKK1).</title>
    </caption>
    <graphic mimetype="image" position="float" xlink:type="simple" xlink:href="https://html.scirp.org/file/2070628-rId17.jpeg?20240930044955" />
   </fig>
   <p>
    <xref ref-type="bibr" rid="scirp.136449-"></xref>investigating the correlation between sclerostin and Dickkopf-1 and intima-media thickness (IMT), peak systolic velocity of the main arteries, and traditional calcification markers.</p>
   <p>The current study found that children undergoing maintenance hemodialysis showed significantly increased levels of sclerostin and Dickkopf-1 in their serum. As chronic kidney disease progresses, plasma sclerostin levels rise, reaching the highest levels in HD patients <xref ref-type="bibr" rid="scirp.136449-21">
     [21]
    </xref>. However, the role of serum sclerostin and Dickkopf-1 in patients with CKD varies across different studies. Some investigations have shown positive correlations, while others have suggested no or even</p>
   <fig id="fig5" position="float">
    <label>Figure 5</label>
    <caption>
     <title>Figure 5. ROC curve for sclerostin and Dickkopf-1in predicting cardiovascular risk in children on maintenance hemodialysis.</title>
    </caption>
    <graphic mimetype="image" position="float" xlink:type="simple" xlink:href="https://html.scirp.org/file/2070628-rId18.jpeg?20240930044955" />
   </fig>
   <p>negative correlations <xref ref-type="bibr" rid="scirp.136449-16">
     [16]
    </xref>.</p>
   <p>The current study recorded a significant increase in the IMT of the main arteries and carotid, ulnar, and brachial arteries in children undergoing hemodialysis. The thickness was notably higher in the hemodialysis group than in the control group.</p>
   <p>Vascular calcification (VC) is the bone-like material forming in blood vessels due to inflammatory factors. However, the specific mechanisms behind VC in patients with chronic kidney disease (CKD) are not fully understood yet. One known mechanism involves transforming vascular smooth muscle cells (VSMCs) into cells similar to bone tissue within the arteries <xref ref-type="bibr" rid="scirp.136449-22">
     [22]
    </xref> <xref ref-type="bibr" rid="scirp.136449-23">
     [23]
    </xref>.</p>
   <p>Furthermore, atherosclerosis, a chronic inflammatory condition, significantly contributes to cardiovascular diseases by causing plaque rupture and thrombosis, as emphasised <xref ref-type="bibr" rid="scirp.136449-24">
     [24]
    </xref> <xref ref-type="bibr" rid="scirp.136449-25">
     [25]
    </xref>. Exciting research has found a significant positive correlation between Sclerostin and Dickkopf-1 levels and the thickness of the carotid, ulnar, and brachial arteries in hemodialysis patients. This study suggests that sclerostin may directly affect atherosclerosis through biological mechanisms related to Wnt signalling. Previous research has linked Wnt signalling to the development of atherosclerosis. <xref ref-type="bibr" rid="scirp.136449-26">
     [26]
    </xref>. However, as Wnt inhibitors, sclerostin and Dickkopf-1 are predicted to protect against atherosclerosis instead of increasing its risk. Although sclerostin and Dickkopf-1 inhibit skeletal mineralization, this is secondary to their effect on bone formation and osteoblast function and represents an entirely distinct process of vascular calcification <xref ref-type="bibr" rid="scirp.136449-27">
     [27]
    </xref> <xref ref-type="bibr" rid="scirp.136449-28">
     [28]
    </xref>.</p>
   <p>Sclerostin and Dickkopf-1 inhibit the canonical Wnt signalling pathway, which controls cellular proliferation and differentiation and regulates bone formation, immune responses <xref ref-type="bibr" rid="scirp.136449-19">
     [19]
    </xref>, atherosclerosis, and vascular calcification <xref ref-type="bibr" rid="scirp.136449-29">
     [29]
    </xref> <xref ref-type="bibr" rid="scirp.136449-30">
     [30]
    </xref>.</p>
   <p>The presence of sclerostin in vascular tissue suggests it might directly affect vascular calcification and atherosclerosis, consistent with previous observations <xref ref-type="bibr" rid="scirp.136449-31">
     [31]
    </xref> <xref ref-type="bibr" rid="scirp.136449-32">
     [32]
    </xref>.</p>
   <p>Canonical Wnt signalling differentiates progenitor and vascular smooth muscle cells in vascular calcification into osteo/chondrogenic phenotypes <xref ref-type="bibr" rid="scirp.136449-33">
     [33]
    </xref>. Both dickkopf-1 and sclerostin <xref ref-type="bibr" rid="scirp.136449-34">
     [34]
    </xref> <xref ref-type="bibr" rid="scirp.136449-35">
     [35]
    </xref> reduce the expression of runt-related transcription factor 2, which is crucial for osteogenic differentiation <xref ref-type="bibr" rid="scirp.136449-36">
     [36]
    </xref>.</p>
   <p>Numerous studies have unequivocally established a direct positive correlation between serum sclerostin concentration and the severity of aortic valve, coronary, or aortic calcification across diverse populations, encompassing patients with end-stage renal disease (ESRD), less severe CKD, healthy men, and postmenopausal women <xref ref-type="bibr" rid="scirp.136449-37">
     [37]
    </xref>-<xref ref-type="bibr" rid="scirp.136449-38">
     [38]
    </xref>.</p>
   <p>In a study of rheumatoid arthritis patients, a clear association was found between serum sclerostin levels and the severity of aortic calcification. However, no association was observed with the severity of coronary artery calcification <xref ref-type="bibr" rid="scirp.136449-39">
     [39]
    </xref>.</p>
   <p>It was established that there is an inverse association between serum sclerostin concentration and the severity of abdominal aortic calcification in patients with ESRD <xref ref-type="bibr" rid="scirp.136449-40">
     [40]
    </xref>. Di M et al. found that overexpression of Dickkopf-1 results in enlarged and destabilised atherosclerotic lesions and increased apoptosis in aortic and carotid plaque <xref ref-type="bibr" rid="scirp.136449-41">
     [41]
    </xref>.</p>
   <p>The current study showed a significant decrease in the main arteries’ peak systolic velocity (PSV). Pulse-wave velocity (PWV) is an unquestionably reliable indicator of arterial stiffness. It is widely acknowledged as an independent predictor of cardiovascular events and mortality in patients with chronic kidney disease (CKD) who require hemodialysis <xref ref-type="bibr" rid="scirp.136449-42">
     [42]
    </xref>.</p>
   <p>This study found that the decrease in PWV was significantly correlated with the levels of sclerostin and Dickkopf-1. Previous studies have shown a negative relationship between circulating Dickkopf-1 and arterial stiffness in patients with CKD <xref ref-type="bibr" rid="scirp.136449-43">
     [43]
    </xref>. The current study reported a significant association of sclerostin and Dickkopf-1 with systolic and diastolic blood pressure, which could be explained by arterial sclerosis and reduced PSV in these patients. Thickened cIMT is strongly associated with incident hypertension risk <xref ref-type="bibr" rid="scirp.136449-44">
     [44]
    </xref>.</p>
   <p>We observed a significant correlation between Dickkopf-1 and sclerostin and CRP and platelets. Dickkopf-1 is linked to inflammation, platelet activation, and endothelial dysfunction, and it plays a crucial role in the early stages of atherosclerosis. In an inflammatory environment within the atherosclerotic plaques, activated platelets release Dickkopf-1. This inhibits the Wnt/β-catenin pathway in endothelial cells and contributes to the atherosclerotic process <xref ref-type="bibr" rid="scirp.136449-45">
     [45]
    </xref>.</p>
   <p>Our analysis revealed a significant correlation between sclerostin, cholesterol, and triglycerides. However, we did not examine any other lipid profiles. In terms of the potential role of abnormal lipid metabolism in mediating the connection between sclerostin and cardiovascular disease, a previous study also discovered a positive link between sclerostin and LDL cholesterol <xref ref-type="bibr" rid="scirp.136449-46">
     [46]
    </xref>, which is consistent with our current findings. This may represent another mechanism through which sclerostin influences CVD risk.</p>
  </sec><sec id="s4">
   <title>4. Limitations of the Study</title>
   <p>Not many studies focus on this issue in the pediatric age group.</p>
  </sec><sec id="s5">
   <title>5. Conclusion</title>
   <p>The current study implicates sclerostin and Dickkopf-1 in vascular calcification, and they are highly independent early predictors of vascular calcification in children on maintenance hemodialysis.</p>
  </sec><sec id="s6">
   <title>6. Recommendation</title>
   <p>Further research is required to comprehend the roles of Dickkopf-1 and sclerostin in the pathophysiology of vascular calcification.</p>
  </sec>
 </body><back>
  <ref-list>
   <title>References</title>
   <ref id="scirp.136449-ref1">
    <label>1</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Mitsnefes, M.M. (2012) Cardiovascular Disease in Children with Chronic Kidney Disease. Journal of the American Society of Nephrology, 23, 578-585. &gt;https://doi.org/10.1681/asn.2011111115
    </mixed-citation>
   </ref>
   <ref id="scirp.136449-ref2">
    <label>2</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Georgianos, P.I., Sarafidis, P.A. and Lasaridis, A.N. (2015) Arterial Stiffness: A Novel Cardiovascular Risk Factor in Kidney Disease Patients. Current Vascular Pharmacology, 13, 229-238. &gt;https://doi.org/10.2174/15701611113119990147 
    </mixed-citation>
   </ref>
   <ref id="scirp.136449-ref3">
    <label>3</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Memmos, E., Sarafidis, P., Pateinakis, P., Tsiantoulas, A., Faitatzidou, D., Giamalis, P., et al. (2019) Soluble Klotho Is Associated with Mortality and Cardiovascular Events in Hemodialysis. BMC Nephrology, 20, Article No. 217. &gt;https://doi.org/10.1186/s12882-019-1391-1
    </mixed-citation>
   </ref>
   <ref id="scirp.136449-ref4">
    <label>4</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Chavers, B.M., Molony, J.T., Solid, C.A., Rheault, M.N. and Collins, A.J. (2015) One-Year Mortality Rates in US Children with End-Stage Renal Disease. American Journal of Nephrology, 41, 121-128. &gt;https://doi.org/10.1159/000380828
    </mixed-citation>
   </ref>
   <ref id="scirp.136449-ref5">
    <label>5</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Guérin, A.P., Pannier, B., Marchais, S.J. and London, G.M. (2008) Arterial Structure and Function in End-Stage Renal Disease. Current Hypertension Reports, 10, 107-111. &gt;https://doi.org/10.1007/s11906-008-0021-2
    </mixed-citation>
   </ref>
   <ref id="scirp.136449-ref6">
    <label>6</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Shroff, R.C., Donald, A.E., Hiorns, M.P., Watson, A., Feather, S., Milford, D., et al. (2007) Mineral Metabolism and Vascular Damage in Children on Dialysis. Journal of the American Society of Nephrology, 18, 2996-3003. &gt;https://doi.org/10.1681/asn.2006121397
    </mixed-citation>
   </ref>
   <ref id="scirp.136449-ref7">
    <label>7</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Litwin, M., Wu, E., Jourdan, C., Trelewicz, J., Niemirska, A., Fahr, K., et al. (2005) Altered Morphologic Properties of Large Arteries in Children with Chronic Renal Failure and after Renal Transplantation. Journal of the American Society of Nephrology, 16, 1494-1500. &gt;https://doi.org/10.1681/asn.2004110932
    </mixed-citation>
   </ref>
   <ref id="scirp.136449-ref8">
    <label>8</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Schaefer, F., Doyon, A., Azukaitis, K., Bayazit, A., Canpolat, N., Duzova, A., et al. (2016) Cardiovascular Phenotypes in Children with CKD: The 4C Study. Clinical Journal of the American Society of Nephrology, 12, 19-28. &gt;https://doi.org/10.2215/cjn.01090216 
    </mixed-citation>
   </ref>
   <ref id="scirp.136449-ref9">
    <label>9</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Shroff, R.C., McNair, R., Figg, N., Skepper, J.N., Schurgers, L., Gupta, A., et al. (2008) Dialysis Accelerates Medial Vascular Calcification in Part by Triggering Smooth Muscle Cell Apoptosis. Circulation, 118, 1748-1757. &gt;https://doi.org/10.1161/circulationaha.108.783738
    </mixed-citation>
   </ref>
   <ref id="scirp.136449-ref10">
    <label>10</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Shroff, R.C., McNair, R., Skepper, J.N., Figg, N., Schurgers, L.J., Deanfield, J., et al. (2010) Chronic Mineral Dysregulation Promotes Vascular Smooth Muscle Cell Adaptation and Extracellular Matrix Calcification. Journal of the American Society of Nephrology, 21, 103-112. &gt;https://doi.org/10.1681/asn.2009060640
    </mixed-citation>
   </ref>
   <ref id="scirp.136449-ref11">
    <label>11</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Shroff, R., Long, D.A. and Shanahan, C. (2013) Mechanistic Insights into Vascular Calcification in CKD. Journal of the American Society of Nephrology, 24, 179-189. &gt;https://doi.org/10.1681/asn.2011121191 
    </mixed-citation>
   </ref>
   <ref id="scirp.136449-ref12">
    <label>12</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Mitsnefes, M.M. (2008) Cardiovascular Complications of Pediatric Chronic Kidney Disease. Pediatric Nephrology, 23, 27-39. &gt;https://doi.org/10.1007/s00467-006-0359-0 
    </mixed-citation>
   </ref>
   <ref id="scirp.136449-ref13">
    <label>13</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Baron, R. and Kneissel, M. (2013) WNT Signaling in Bone Homeostasis and Disease: From Human Mutations to Treatments. Nature Medicine, 19, 179-192. &gt;https://doi.org/10.1038/nm.3074
    </mixed-citation>
   </ref>
   <ref id="scirp.136449-ref14">
    <label>14</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Monroe, D.G., McGee-Lawrence, M.E., Oursler, M.J. and Westendorf, J.J. (2012) Update on Wnt Signaling in Bone Cell Biology and Bone Disease. Gene, 492, 1-18. &gt;https://doi.org/10.1016/j.gene.2011.10.044
    </mixed-citation>
   </ref>
   <ref id="scirp.136449-ref15">
    <label>15</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Evenepoel, P., D’Haese, P. and Brandenburg, V. (2015) Sclerostin and DKK1: New Players in Renal Bone and Vascular Disease. Kidney International, 88, 235-240. &gt;https://doi.org/10.1038/ki.2015.156
    </mixed-citation>
   </ref>
   <ref id="scirp.136449-ref16">
    <label>16</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Cejka, D., Herberth, J., Branscum, A.J., Fardo, D.W., Monier-Faugere, M., Diarra, D., et al. (2011) Sclerostin and Dickkopf-1 in Renal Osteodystrophy. Clinical Journal of the American Society of Nephrology, 6, 877-882. &gt;https://doi.org/10.2215/cjn.06550810 
    </mixed-citation>
   </ref>
   <ref id="scirp.136449-ref17">
    <label>17</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Golledge, J. and Thanigaimani, S. (2022) Role of Sclerostin in Cardiovascular Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 42, e187-e202. &gt;https://doi.org/10.1161/atvbaha.122.317635 
    </mixed-citation>
   </ref>
   <ref id="scirp.136449-ref18">
    <label>18</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Krishna, S.M., Seto, S., Jose, R.J., Li, J., Morton, S.K., Biros, E., et al. (2017) Wnt Signaling Pathway Inhibitor Sclerostin Inhibits Angiotensin Ii-Induced Aortic Aneurysm and Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 37, 553-566. &gt;https://doi.org/10.1161/atvbaha.116.308723 
    </mixed-citation>
   </ref>
   <ref id="scirp.136449-ref19">
    <label>19</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Kidney Disease: Improving Global Outcomes (KDIGO) ANCA Vasculitis Work Group (2024) KDIGO 2024 Clinical Practice Guideline for the Management of Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis. Kidney International, 105, S71-S116. &gt;https://doi.org/10.1016/j.kint.2023.10.008
    </mixed-citation>
   </ref>
   <ref id="scirp.136449-ref20">
    <label>20</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Jayanthi, K.B., Rajasekaran, C., Madian, N. and Thyagarajah, K. (2017). Analysis on Various Segmentation Techniques—IMT Measurement of Common Carotid Artery. TENCON 2017-2017 IEEE Region 10 Conference, Penang, 5-8 November 2017, 2435-2440. &gt;https://doi.org/10.1109/tencon.2017.8228270
    </mixed-citation>
   </ref>
   <ref id="scirp.136449-ref21">
    <label>21</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Claes, K.J., Viaene, L., Heye, S., Meijers, B., d’Haese, P. and Evenepoel, P. (2013) Sclerostin: Another Vascular Calcification Inhibitor? The Journal of Clinical Endocrinology&amp;Metabolism, 98, 3221-3228. &gt;https://doi.org/10.1210/jc.2013-1521
    </mixed-citation>
   </ref>
   <ref id="scirp.136449-ref22">
    <label>22</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Evenepoel, P., Goffin, E., Meijers, B., Kanaan, N., Bammens, B., Coche, E., et al. (2015) Sclerostin Serum Levels and Vascular Calcification Progression in Prevalent Renal Transplant Recipients. The Journal of Clinical Endocrinology&amp;Metabolism, 100, 4669-4676. &gt;https://doi.org/10.1210/jc.2015-3056
    </mixed-citation>
   </ref>
   <ref id="scirp.136449-ref23">
    <label>23</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Speer, M.Y., Yang, H., Brabb, T., Leaf, E., Look, A., Lin, W., et al. (2009) Smooth Muscle Cells Give Rise to Osteochondrogenic Precursors and Chondrocytes in Calcifying Arteries. Circulation Research, 104, 733-741. &gt;https://doi.org/10.1161/circresaha.108.183053
    </mixed-citation>
   </ref>
   <ref id="scirp.136449-ref24">
    <label>24</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Lusis, A.J. (2000) Atherosclerosis. Nature, 407, 233-241. &gt;https://doi.org/10.1038/35025203
    </mixed-citation>
   </ref>
   <ref id="scirp.136449-ref25">
    <label>25</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Herrington, W., Lacey, B., Sherliker, P., Armitage, J. and Lewington, S. (2016) Epidemiology of Atherosclerosis and the Potential to Reduce the Global Burden of Atherothrombotic Disease. Circulation Research, 118, 535-546. &gt;https://doi.org/10.1161/circresaha.115.307611
    </mixed-citation>
   </ref>
   <ref id="scirp.136449-ref26">
    <label>26</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Clevers, H. (2006) Wnt/β-Catenin Signaling in Development and Disease. Cell, 127, 469-480. &gt;https://doi.org/10.1016/j.cell.2006.10.018
    </mixed-citation>
   </ref>
   <ref id="scirp.136449-ref27">
    <label>27</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Catalano, A., Bellone, F., Morabito, N. and Corica, F. (2020) Sclerostin and Vascular Pathophysiology. International Journal of Molecular Sciences, 21, Article No. 4779. &gt;https://doi.org/10.3390/ijms21134779
    </mixed-citation>
   </ref>
   <ref id="scirp.136449-ref28">
    <label>28</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Koos, R., Brandenburg, V., Mahnken, A.H., et al. (2013) Sclerostin as a Potential Novel Biomarker for Aortic Valve Calcification: An in-vivo and ex-vivo Study. The Journal of Heart Valve Disease, 22, 317-325. 
    </mixed-citation>
   </ref>
   <ref id="scirp.136449-ref29">
    <label>29</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Chae, W. and Bothwell, A.L.M. (2018) Canonical and Non-Canonical Wnt Signaling in Immune Cells. Trends in Immunology, 39, 830-847. &gt;https://doi.org/10.1016/j.it.2018.08.006
    </mixed-citation>
   </ref>
   <ref id="scirp.136449-ref30">
    <label>30</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Foulquier, S., Daskalopoulos, E.P., Lluri, G., Hermans, K.C.M., Deb, A. and Blankesteijn, W.M. (2017) WNT Signaling in Cardiac and Vascular Disease. Pharmacological Reviews, 70, 68-141. &gt;https://doi.org/10.1124/pr.117.013896
    </mixed-citation>
   </ref>
   <ref id="scirp.136449-ref31">
    <label>31</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Sage, A.P., Tintut, Y. and Demer, L.L. (2010) Regulatory Mechanisms in Vascular Calcification. Nature Reviews Cardiology, 7, 528-536. &gt;https://doi.org/10.1038/nrcardio.2010.115
    </mixed-citation>
   </ref>
   <ref id="scirp.136449-ref32">
    <label>32</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Shao, J., Cai, J. and Towler, D.A. (2006) Molecular Mechanisms of Vascular Calcification. Arteriosclerosis, Thrombosis, and Vascular Biology, 26, 1423-1430. &gt;https://doi.org/10.1161/01.atv.0000220441.42041.20
    </mixed-citation>
   </ref>
   <ref id="scirp.136449-ref33">
    <label>33</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Cai, T., Sun, D., Duan, Y., Wen, P., Dai, C., Yang, J., et al. (2016) WNT/β-Catenin Signaling Promotes VSMCs to Osteogenic Transdifferentiation and Calcification through Directly Modulating Runx2 Gene Expression. Experimental Cell Research, 345, 206-217. &gt;https://doi.org/10.1016/j.yexcr.2016.06.007
    </mixed-citation>
   </ref>
   <ref id="scirp.136449-ref34">
    <label>34</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     M. McArthur, K., M. Kay, A., A. Mosier, J., N. Grant, J., A. Stewart, J. and LaShan Simpson, C. (2017) Manipulating the Plasticity of Smooth Muscle Cells to Regulate Vascular Calcification. AIMS Cell and Tissue Engineering, 1, 165-179. &gt;https://doi.org/10.3934/celltissue.2017.3.165
    </mixed-citation>
   </ref>
   <ref id="scirp.136449-ref35">
    <label>35</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Nguyen-Yamamoto, L., Tanaka, K., St-Arnaud, R. and Goltzman, D. (2019) Vitamin D-Regulated Osteocytic Sclerostin and BMP2 Modulate Uremic Extraskeletal Calcification. JCI Insight, 4, Article 126467. &gt;https://doi.org/10.1172/jci.insight.126467
    </mixed-citation>
   </ref>
   <ref id="scirp.136449-ref36">
    <label>36</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Mori, H., Torii, S., Kutyna, M., Sakamoto, A., Finn, A.V. and Virmani, R. (2018) Coronary Artery Calcification and Its Progression. JACC: Cardiovascular Imaging, 11, 127-142. &gt;https://doi.org/10.1016/j.jcmg.2017.10.012
    </mixed-citation>
   </ref>
   <ref id="scirp.136449-ref37">
    <label>37</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Li, M., Zhou, H., Yang, M. and Xing, C. (2018) Relationship between Serum Sclerostin, Vascular Sclerostin Expression and Vascular Calcification Assessed by Different Methods in ESRD Patients Eligible for Renal Transplantation: A Cross-Sectional Study. International Urology and Nephrology, 51, 311-323. &gt;https://doi.org/10.1007/s11255-018-2033-4
    </mixed-citation>
   </ref>
   <ref id="scirp.136449-ref38">
    <label>38</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Qureshi, A.R., Olauson, H., Witasp, A., Haarhaus, M., Brandenburg, V., Wernerson, A., et al. (2015) Increased Circulating Sclerostin Levels in End-Stage Renal Disease Predict Biopsy-Verified Vascular Medial Calcification and Coronary Artery Calcification. Kidney International, 88, 1356-1364. &gt;https://doi.org/10.1038/ki.2015.194
    </mixed-citation>
   </ref>
   <ref id="scirp.136449-ref39">
    <label>39</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Pelletier, S., Confavreux, C.B., Haesebaert, J., Guebre-Egziabher, F., Bacchetta, J., Carlier, M.-C., et al. (2015) Serum Sclerostin: The Missing Link in the Bone-Vessel Cross-Talk in Hemodialysis Patients? Osteoporosis International, 26, 2165-2174. &gt;https://doi.org/10.1007/s00198-015-3127-9
    </mixed-citation>
   </ref>
   <ref id="scirp.136449-ref40">
    <label>40</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Paccou, J., Mentaverri, R., Renard, C., Liabeuf, S., Fardellone, P., Massy, Z.A., et al. (2014) The Relationships between Serum Sclerostin, Bone Mineral Density, and Vascular Calcification in Rheumatoid Arthritis. The Journal of Clinical Endocrinology&amp;Metabolism, 99, 4740-4748. &gt;https://doi.org/10.1210/jc.2014-2327
    </mixed-citation>
   </ref>
   <ref id="scirp.136449-ref41">
    <label>41</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Lee, Y., Ng, H., Chiu, T.T., Li, L., Pei, S., Kuo, W., et al. (2016) Association of Bone-Derived Biomarkers with Vascular Calcification in Chronic Hemodialysis Patients. Clinica Chimica Acta, 452, 38-43. &gt;https://doi.org/10.1016/j.cca.2015.10.031
    </mixed-citation>
   </ref>
   <ref id="scirp.136449-ref42">
    <label>42</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Thambiah, S., Roplekar, R., Manghat, P., Fogelman, I., Fraser, W.D., Goldsmith, D., et al. (2012) Circulating Sclerostin and Dickkopf-1 (DKK1) in Predialysis Chronic Kidney Disease (CKD): Relationship with Bone Density and Arterial Stiffness. Calcified Tissue International, 90, 473-480. &gt;https://doi.org/10.1007/s00223-012-9595-4 
    </mixed-citation>
   </ref>
   <ref id="scirp.136449-ref43">
    <label>43</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Sarafidis, P.A., Loutradis, C., Karpetas, A., Tzanis, G., Piperidou, A., Koutroumpas, G., et al. (2017) Ambulatory Pulse Wave Velocity Is a Stronger Predictor of Cardiovascular Events and All-Cause Mortality than Office and Ambulatory Blood Pressure in Hemodialysis Patients. Hypertension, 70, 148-157. &gt;https://doi.org/10.1161/hypertensionaha.117.09023
    </mixed-citation>
   </ref>
   <ref id="scirp.136449-ref44">
    <label>44</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Ueland, T., Otterdal, K., Lekva, T., Halvorsen, B., Gabrielsen, A., Sandberg, W.J., et al. (2009) Dickkopf-1 Enhances Inflammatory Interaction between Platelets and Endothelial Cells and Shows Increased Expression in Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 29, 1228-1234. &gt;https://doi.org/10.1161/atvbaha.109.189761
    </mixed-citation>
   </ref>
   <ref id="scirp.136449-ref45">
    <label>45</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Mikheev, A.M., Mikheeva, S.A., Maxwell, J., Rivo, J.V., Rostomily, R., Swisshelm, K., et al. (2007) Dickkopf-1 Mediated Tumor Suppression in Human Breast Carcinoma Cells. Breast Cancer Research and Treatment, 112, 263-273. &gt;https://doi.org/10.1007/s10549-007-9867-2 
    </mixed-citation>
   </ref>
   <ref id="scirp.136449-ref46">
    <label>46</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Urano, T., Shiraki, M., Ouchi, Y. and Inoue, S. (2012) Association of Circulating Sclerostin Levels with Fat Mass and Metabolic Disease—Related Markers in Japanese Postmenopausal Women. The Journal of Clinical Endocrinology&amp;Metabolism, 97, E1473-E1477. &gt;https://doi.org/10.1210/jc.2012-1218
    </mixed-citation>
   </ref>
  </ref-list>
 </back>
</article>